NL-OMON48676RecruitingNot Applicable
Determining prognostic immune markers in patients with ovarian cancer * a prospective explorative cohort study. - IMPrOVE
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •* Patients with (suspicion of) primary or recurrent EOC with an indication for
- •surgery, chemotherapy and/or immunotherapy.
- •* Age *18 years.
- •* WHO performance status 0-2.
- •* Accessible for treatment and follow-up.
- •* Written informed consent.
Exclusion Criteria
- •* Other active malignancy in past 5 years prior to entry into the study, except
- •for treated non-melanoma skin cancer.
- •* Any known severe infection like HIV, hepatitis A, B and C.
- •* Receiving immune suppressive treatment.
- •* Medical or psychological condition which in the opinion of the investigator
- •would not permit the patient to complete the study or sign meaningful informed
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000047162Kobe University114
Recruiting
Not Applicable
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
Recruiting
Not Applicable
Prospective immune biomarker identification trial for renal cell carcinoma treatment.Renal cell carcinomaJPRN-UMIN000047119Keio University, school of medicine100
Unknown
Not Applicable
Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung CancerLung CancerNCT04918836University Hospital, Brest150
Completed
Not Applicable
Can Immunohistochemical markers be a prognostic factors in malignant pleural mesothelioma patients?Malignant pleural mesotheliomaJPRN-UMIN000015825Hyogo Prefectural Amagasaki Hospital350